Navigation Links
AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
Date:3/1/2012

IRVINE, Calif., March 1, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, today announced that it has initiated the first shipment of AHRO-001 Active Pharmaceutical Ingredient (API) to its research and development partner CardioNova, Ltd., a Russia based biotech company responsible for Phase 1 and 2 human clinical studies of AHRO-001. The clinical-grade material will be used to commence the toxicology studies conducted for Russian regulatory purposes.

"We are pleased to announce this first shipment, clearly a milestone for us in the development of AHRO-001 for use in upcoming human clinical studies," said AtheroNova CEO Thomas Gardner. "This is the highest purity ever achieved in AHRO-001 and is ready to be used in an advanced clinical setting for the first time. As we proceed through our clinical phases, we are extremely gratified to adhere to our aggressive development path and look forward to additional development milestones in the coming months."

"CardioNova is very excited to receive the first shipment," commented CardioNova CEO Andrey Boldyrev. "We are looking forward to starting the toxicology studies and initiating clinical studies in close cooperation with AtheroNova, who proves to be an ideal partner for this project. We believe that an effective partnership of our two companies will allow us to bring to market a novel drug that is much anticipated by doctors and patients all over the world."

About AHRO-001
AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain natural compounds to regress atherosclerotic plaque deposits through a process known as delipidization. Delipidization dissolves plaques in artery walls, which are the
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AtheroNova Announces a New Board Member
2. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
3. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
4. AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
5. GenVec Achieves Second Milestone in Collaboration
6. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
7. MedNet Solutions Achieves the Inc. 5000 List Five Years in a Row
8. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
9. New compact microspectrometer design achieves high resolution and wide bandwidth
10. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
11. Leading Animal Stem Cell Developer MediVet-America Achieves Significant Business Growth Milestones in First Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the ... for the public comment period (Docket No. FAA-2014-0396) for ... established by Congress as part of the FAA Modernization ... the new deadline for comments as September 23, 2014. ... published in the Federal Register on July 25, 2014, ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, announced today ... a presentation to investors on Tuesday, July 29, ...  The presentation will include an overview of Asterias, ... the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... FRANCISCO, June 7, 2011 Vaxart, Inc., a San Francisco ... a Phase I clinical trial. This is the first clinical ... platform technology. The trial site is in the United States. ... if safety is demonstrated with one vaccine, we can expect ...
... YORK, June 7, 2011 DuPont (NYSE: ... told investors at the JPMorgan Diversified Industries Conference to ... process innovation, selective investment in attractive areas, broad-based growth, ... productivity.  Kullman also reaffirmed DuPont,s 2011 earnings per share ...
... Infrared Systems International (OTCBB: IFRS) is pleased to announce ... of its NatuRx™ HIV/AIDS treatment and will push forward with ... concluded a pilot study with two HIV/AIDS patients this week ... first reported AIDS victims on June 5th, 1981. ...
Cached Biology Technology:Vaxart Begins First Oral Vaccine Clinical Trial 2DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 2DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 3Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 3
(Date:7/28/2014)... other forms of dementia, but the research community is ... Washington bioengineers have a designed a peptide structure that ... proteins into a state that,s linked to widespread diseases ... and Lou Gehrig,s disease. The synthetic molecule blocks these ... an abnormally folded form by targeting a toxic intermediate ...
(Date:7/28/2014)... He calls himself the bug hunter, but the target ... be found and identified with special methods and instruments. ... State Veterinary Diagnostic Laboratory at Kansas State University, recently ... enterovirus G, which is an important find in the ... cells, but didn,t know what it was," Hause said. ...
(Date:7/28/2014)... 28, 2014)The Brain & Behavior Research Foundation today ... Freedman Prizes, recognizing exceptional clinical and basic research ... NARSAD Young Investigator Grants. The grants enable early ... and psychosocial research for the prevention, early detection, ... one in four people. , Six young scientistswinners ...
Breaking Biology News(10 mins):New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4
... 2012)A new study led by North Carolina researchers has ... loss, aerobic training is better than resistance training. The ... directly compare changes in body composition induced by comparable ... or both in combination, among previously inactive overweight or ...
... , This press release is available in ... Agriculture (USDA) scientists are developing strategies to help livestock ... of cattle in the United States. ... Research Service (ARS) Agroecosystem Management Research Unit (AMRU) in ...
... Amid growing concern over the surprisingly large amount ... other telecommunications activities, researchers are reporting new models ... reduce their carbon footprint. Their report appears in ... Researchers from the Centre for Energy-Efficient ...
Cached Biology News:For those short on time, aerobic, not resistance, exercise is best bet for weight, fat loss 2Treating stable flies in pastures 2
... active ingredient in Molecular Probes. SlowFadeAntifade ... to act as a free radical ... Our original SlowFade formulation (S-2828) was ... of fluorescein to almost zero (Figure ...
b6-2A12...
... in this kit are prepared with pure ... Biochains Mitochondria Isolation Kit is designed to ... fast and easy way. One kit is ... isolations (enriching mitochondria from 10 20 ...
... The Freedom EVOlyzer is Tecans new ... automated microplate processing. Freedom EVOlyzer is a ... includes state-of-the art reader, washer and incubation ... software. The Freedom EVOlyzer is available in ...
Biology Products: